Pre-Open Stock Movers 05/03: (MDP) (OCGN) (VIRX) Higher; (VXRT) (PETS) (EL) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vaxart (VXRT) Reports First Patient Enrollment in Phase 1b Norovirus Boosting Regimen Study
May 5, 2021 6:20 AM EDTVaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate. This study is designed to evaluate the safety and immunogenicity of various dosing intervals for Vaxarts candidate, which is the only clinical stage norovirus oral tablet vaccine actively being developed.
In a health economic study published in the American Journal of Preventative Medicine in January... More
Clorox (CLX) PT Lowered to $195 at Jefferies
May 4, 2021 6:00 AM EDTJefferies analyst Kevin Grundy lowered the price target on Clorox (NYSE: CLX) to $195.00 (from $205.00) while maintaining a Hold rating.
The analyst comments "We trim our FY22-23 EPS ests.... More
